Investor Presentaiton
Drug Discovery & Development Solutions - Q3'FY20
Revenue
Particulars¹
Q3'FY19 Q3'FY20 % Change
54
68
26%
Drug Discovery Services
54
68
26%
Proprietary Drug Discovery
0
0
Reported EBITDA
17
270%
Drug Discovery Services
5
21
353%
Proprietary Drug Discovery
0
(4)
Reported EBITDA Margin (%)
Drug Discovery Services
8.6%
25.4%
8.6%
31.1%
Geography Wise Revenue¹
42
52
39
■ Drug Discovery & Development Solutions (DDDS) comprises
.
•
Drug Discovery Services business through Jubilant Biosys
Limited & Jubilant Chemsys Limited provides innovation and
collaborative research through two world class research
centers in Noida and Bangalore in India
Proprietary Drug Discovery business through Jubilant
Therapeutics, a semi-virtual biopharma company, with a
business model of targeting small molecule therapies in the
area of oncology and auto-immune disorders
■ DDDS revenue increased by 26% YoY to Rs 68 Crore led by growth
in Drug Discovery Services business
•
15
14
•
01
01
India
Q3'FY19
North America Europe & Japan
■Q3'FY20
ROW
•
Drug Discovery Services business grew by 26% driven by
higher demand from Biotech companies for Integrated
Services, DMPK, Chemistry & Scale-up
Proprietary Drug Discovery business currently has more than
six programs at different stages with potential to partner
and/or fast track from discovery to clinical stage
Revenue from North America increased by 34% YoY.
1. All figures are in Rs Crore unless otherwise stated
■ EBITDA at Rs 17 Crore with margin of 25.4%
•
Drug Discovery Services EBITDA increased to Rs 21 Crore from
Rs 5 Crore in Q3'FY19. Margin improvement to 31.1% from
8.6% in Q3'FY19
JUBILANT
LIFESCIENCESView entire presentation